Benitec Biopharma Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Benitec Biopharma Inc. (BNTC) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2025Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Operating Activities
Net Income-37.92-21.75-19.56-18.21-13.88-8.27
Depreciation & Amortization0.400.340.380.390.420.37
Stock Based Compensation17.430.830.450.870.630.00
Change in Working Capital-2.731.170.711.040.021.94
Change in Accounts Receivable0.20-0.18-0.050.000.030.00
Change in Accounts Payable-2.380.941.361.090.060.00
Change in Other Working Capital-0.550.41-0.59-0.05-0.080.00
Other Operating Activities-0.760.830.460.880.62-1.63
Net Cash from Operating Activities-23.59-19.40-18.01-15.90-12.80-7.54
Investing Activities
Capital Expenditures-0.02-0.180.00-0.010.220.10
Net Cash from Investing Activities-0.02-0.180.00-0.01-0.22-0.09
Financing Activities
Common Stock Issued70.4970.8817.880.0025.752.25
Other Financing Activities0.00-5.89-1.870.00-3.230.00
Net Cash from Financing Activities70.4968.0316.020.0022.521.77
Summary
Effect of Forex Changes on Cash0.05-0.010.410.200.500.00
Net Change in Cash46.9348.45-2.00-15.719.47-5.86
Cash at Beginning of Period50.932.494.0819.789.8215.72
Cash at End of Period97.8650.932.494.0819.789.80
Free Cash Flow-23.61-19.58-18.01-15.91-13.02-7.63